

on January 9, 1990 as U.S. Patent No. 4,892,827) entitled "Recombinant Pseudomonas Exotoxins: Construction of an Active Immunotoxin with Low Side Effects", to The Cooperative Research Centre for Biopharmaceutical Research Pty., Ltd., having a place of business in Darlinghurst Australia. The patent rights in these inventions have been assigned to the United States of America.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 60 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

The field of use would be limited to recombinant heregulin PE-40 toxin cancer therapeutics which bind to the ligand binding site of the erbB3 and/or erbB4 proteins.

The present invention relates to modifications of recombinant Pseudomonas exotoxin with insertion of various targeting molecules specific for a given target site. The modified exotoxin of this invention may prove to be a valuable cancer therapeutic when fused to various target-specific cell recognition proteins. The modifications result in reduced non-specific cytotoxicity while increasing target specific cytotoxicity.

ADDRESSES: Requests for a copy of the subject issued patent, inquiries, comments and other materials relating to the contemplated license should be directed to: Mr. Larry M. Tiffany, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852. Telephone: (301) 496-7056; Facsimile: (301) 402-0220. Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before June 10, 1996, will be considered. Comments and objections will not be made available for public inspection and, to the extent permitted by law, will not be subject to disclosure under the Freedom of Information Act, 5 U.S.C. 552.

Dated: March 29, 1996.

Barbara M. McGarey,

Deputy Director, Office of Technology Transfer.

[FR Doc. 96-9001 Filed 4-10-96; 8:45 am]

BILLING CODE 4140-01-M

Prospective Grant of Exclusive License: Gene Therapy for Cancer and Restenosis Applications

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a limited field of use exclusive license in the United States to practice the invention embodied in U.S. Patent Application Number 07/725,076 (issued on October 25, 1994 as U.S. Patent No. 5,358,866) entitled "Cytosine Deaminase Negative Selection for Gene Transfer Techniques and Therapies" and its divisional applications 08/271,874, 08/447,580, 08/447,393, 08/445,203, 08/447,487, 08/449,627, 08/448,867, 08/449,636 and U.S. Patent Serial No. 08/136,113 entitled "Efficient and Selective Adenoviral-Mediated Gene Transfer into Vascular Neointima" and its CIP filed via the PCT (No. USSN has been assigned to date) designating only the US for examination, and all related foreign filings, to GenVec, Inc., having a place of business in Rockville, MD (USA). The patent rights in these inventions have been assigned to the United States of America.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 60 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

The field of use would be limited to Gene Therapy for Cancer and Restenosis applications.

The present inventions relate to a modified bacterial gene for cytosine deaminase and a method of expressing DNA of choice in neointimal cells to reduce their proliferation after vascular injury. Specifically, the CD gene can be used as a negative selectable marker to transfect a targeted cell and deaminate a prodrug, 5-fluorocytosine ("5FC"), into 5-fluorouracil ("5FU") which has cytotoxic effects on the targeted cell. This gene is complementary to the other technology contemplated in this notice by being able to be expressed in neointimal cells through an adenoviral vector. Such expression and subsequent administration of the prodrug results in the reduction in proliferation of the

neointimal cells, particularly after vascular injury.

ADDRESSES: Requests for copies of the subject issued patent and pending patent applications, inquiries, comments and other materials relating to the contemplated license should be directed to: Mr. Larry M. Tiffany, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852. Telephone: (301) 496-7056, ext. 206; Facsimile: (301) 402-0220. A signed Confidentiality Agreement will be required to receive copies of the pending patent applications. Applications for a license to the field of use described in this Notice will be treated as objections to the contemplated license. Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before June 10, 1996, will be considered. Comments and objections will not be made available for public inspection and, to the extent permitted by law, will not be subject to disclosure under the Freedom of Information Act, 5 U.S.C. 552.

Dated: March 29, 1996.

Barbara M. McGarey,

Deputy Director, Office of Technology Transfer.

[FR Doc. 96-9002 Filed 4-10-96; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR-3644-C-03]

Office of the Assistant Secretary for Public and Indian Housing; Announcement of Funding Awards; Community Development Block Grant Program for Indian Tribes and Alaskan Native Villages; Fiscal Year 1994; Correction

AGENCY: Office of the Assistant Secretary for Public and Indian Housing, HUD.

ACTION: Announcement of funding awards; correction.

SUMMARY: This notice corrects the Funding Awards Notice for Community Development Block Grant Program for Indian Tribes and Alaskan Native Villages, published in the Federal Register on March 16, 1995 (60 FR 14293). The purpose of this document is to correct the listing of awardees that appeared in the March 16, 1995 notice.

FOR FURTHER INFORMATION CONTACT: Dom Nessi, Office of Native American Programs, Office of Public and Indian